Switzerland mRNA Synthesis & Manufacturing Market (2024-2029)
The Switzerland mRNA Synthesis & Manufacturing Market was valued at $30.19 Million in 2024 and projected to reach to $36.54 Million by 2029, representing a compound annual growth rate of 3.9%. Switzerland's mRNA synthesis and manufacturing market is poised for sustained growth through 2029, supported by the country's exceptional pharmaceutical infrastructure and research capabilities.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Switzerland mRNA Synthesis & Manufacturing Market Trends and Insights
- Switzerland's position as a global pharmaceutical and biotechnology hub supports steady expansion in mRNA production capabilities and infrastructure.
- The country's advanced research institutions and regulatory framework continue to attract investment in mRNA manufacturing technologies. Driven by increasing demand for mRNA-based therapeutics and vaccines, Switzerland's market benefits from its established life sciences ecosystem and proximity to European markets.
- Between 2024 and 2029, Switzerland is expected to see moderate but consistent growth as contract manufacturing organizations (CMOs) and biopharmaceutical companies expand their mRNA synthesis operations.
- Switzerland's commitment to innovation and quality manufacturing standards positions it as a key player in Europe's mRNA supply chain..
Key Market Statistics
- CAGR (2024-2029) 3.9% CAGR
- Market Size, 2024 ~USD 30.19 Million
- Forecast, 2029 ~USD 36.54 Million
- Country Switzerland
Switzerland mRNA Synthesis & Manufacturing Market Overview
Market Valuation :
Switzerland's mRNA synthesis and manufacturing market reached USD 30.19 million in 2024, with projections to expand to USD 36.54 million by 2029, driven by the country's robust biotech ecosystem.
Steady Growth Trajectory :
The Swiss market is experiencing a CAGR of 3.9% through 2029, outpacing global growth rates and reflecting strong domestic demand for advanced mRNA manufacturing capabilities and infrastructure development.
Pharma & Biotech Hub Status :
Switzerland's established position as a global pharmaceutical and biotechnology center provides significant competitive advantages, with world-class research institutions and manufacturing expertise supporting mRNA sector expansion.
Infrastructure & Innovation :
Advanced research facilities and regulatory frameworks in Switzerland enable rapid development and commercialization of mRNA therapies, attracting both domestic and international investment in manufacturing capabilities.
Switzerland mRNA Synthesis & Manufacturing Market Dynamics
- The 3.9% CAGR reflects steady demand from both established pharmaceutical companies and emerging biotech firms seeking to establish or expand mRNA production facilities.
- Switzerland's regulatory environment, skilled workforce, and proximity to European markets create favorable conditions for continued market expansion. The market outlook remains positive as mRNA technology gains broader therapeutic applications beyond vaccines.
- Swiss manufacturers are well-positioned to capitalize on increasing global demand for mRNA-based treatments, with investments in manufacturing capacity and process optimization expected to drive market growth.
- Collaborations between academic institutions and industry players will further strengthen Switzerland's competitive position in the global mRNA manufacturing landscape..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Analytical And Scientific Instrumentation
- Environmental Testing
- Gas Chromatography
- Polymerase Chain Reaction (PCR)
- Automated Liquid Handling Systems
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Agilent Technologies, Inc.
- Shimadzu Corporation
- Merck KGaA
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- SANOFI
- Merck KGaA
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Switzerland's mRNA synthesis market reached USD 30.19 million in 2024 with projected growth to USD 36.54 million by 2029.
- Switzerland maintains a 3.9% CAGR, reflecting steady but measured expansion in mRNA manufacturing capabilities.
- Switzerland's strong pharmaceutical infrastructure and regulatory environment support continued investment in mRNA production technologies.
- Switzerland's strategic location and expertise position it as a critical hub for European mRNA supply chain development.
mRNA Synthesis & Manufacturing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | MRNA SYNTHESIS & MODIFICATION SERVICES (Service) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5.8% from 2024 to 2029 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 2.23 (2024) |
| Revenue Forecast (Billions) | ~USD 2.96 (2029) |
| Segments Covered | Product, Type, Application, End User, Service, Consumables, Transcription Consumables, Purification Consumables, Analysis & Characterization Consumables |
Switzerland mRNA Synthesis & Manufacturing Market Report Segmentation
9 segment dimensions are covered across the global market.
By Product
- Consumables
- Instruments
By Type
- Analysis & Characterization Consumables
- Analysis Kits And Reagents
- Chromatography Filters & Membrane
- Mrna Profiling Kits
- Mrna Synthesis Kits
- Nucleotides
- Other Products
- Other Purification Consumables
- Other Transcription Consumables
- Plasmid Dna/Dna Templates
- Purification Consumables
- Purification Kits & Reagents
- Rna Polymerases
- Transcription Consumables
- Vectors
By Application
- Cell & Gene Therapies
- Other Applications
- Vaccines
By End User
- Academic & Research Institutions
- Cros & Cdmos
- Cros And Cdmos
- Pharmaceutical & Biotechnology Companies
- Small-Scale Cros & Cdmos
By Service
- Manufacturing & Scale-Up Services
- Mrna Analysis & Characterization Services
- Mrna Purification Services
- Mrna Synthesis & Modification Services
By Consumables
- Analysis & Characterization Consumables
- Purification Consumables
- Transcription Consumables
By Transcription Consumables
- Mrna Profiling Kits
- Mrna Synthesis Kits
- Nucleotides
- Other Transcription Consumables
- Plasmid Dna/Dna Templates
- Rna Polymerases
- Vectors
By Purification Consumables
- Chromatography Filters & Membranes
- Other Purification Consumables
- Purification Kits & Reagents
- Purification Kits And Reagents
By Analysis & Characterization Consumables
- Analysis Kits & Reagents
- Analysis Kits And Reagents
- Other Analysis & Characterization Consumables
SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 11.1 | 8 | 8 | 8.2 | 8.5 | 8.9 | 9.2 | 9.7 | 3.9 |
| CROS & CDMOS | 9.4 | 6.9 | 6.8 | 7 | 7.3 | 7.5 | 7.8 | 8.2 | 3.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 26.2 | 19 | 19 | 19.5 | 20.3 | 21.2 | 22 | 23.2 | 4.1 |
| TOTAL | 46.7 | 33.9 | 33.8 | 34.7 | 36.1 | 37.6 | 39.1 | 41.2 | 4 |
SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 9.4 | 8.1 | 8.1 | 8.4 | 8.9 | 9.5 | 10.1 | 11.1 | 6.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 26.9 | 23.3 | 23.4 | 24.4 | 25.8 | 27.6 | 29.7 | 32.5 | 6.8 |
| SMALL-SCALE CROS & CDMOS | 3.3 | 2.8 | 2.8 | 2.9 | 3 | 3.2 | 3.4 | 3.7 | 5.5 |
| TOTAL | 39.7 | 34.3 | 34.4 | 35.7 | 37.8 | 40.3 | 43.2 | 47.3 | 6.6 |
Target Audience
- Pharmaceutical Manufacturers : Swiss and international pharma companies seeking to establish or expand mRNA manufacturing capabilities need detailed market data to assess investment viability, competitive positioning, and growth potential in Switzerland's biotech ecosystem.
- Biotech & CRO Companies : Contract research and manufacturing organizations require Switzerland-specific market intelligence to identify partnership opportunities, evaluate market demand, and develop targeted business strategies for mRNA synthesis services.
- Investment & Private Equity Firms : Investors evaluating opportunities in Switzerland's mRNA sector need comprehensive market analysis, growth forecasts, and competitive landscape data to make informed investment decisions and identify high-potential portfolio companies.
- Government & Policy Makers : Swiss regulatory bodies and economic development agencies require market insights to inform biotech policy, infrastructure investments, and initiatives supporting the country's mRNA manufacturing competitiveness.
- Research Institutions & Academics : Universities and research centers in Switzerland need market data to align research initiatives with commercial opportunities, secure funding, and establish collaborations that advance mRNA technology development and manufacturing innovation.
Reasons to Buy this Report
- Market-Specific Sizing Data : Access precise valuation figures for Switzerland's mRNA market (USD 30.19M in 2024) with detailed 5-year forecasts, enabling accurate investment planning and resource allocation decisions specific to the Swiss market.
- Competitive Landscape Intelligence : Understand Switzerland's unique position as a global pharma hub and identify key players, manufacturing capabilities, and competitive advantages that differentiate the Swiss mRNA sector from other European markets.
- Growth Opportunity Assessment : Evaluate the 3.9% CAGR trajectory and identify specific growth drivers within Switzerland's advanced research institutions, regulatory environment, and infrastructure investments to guide market entry or expansion strategies.
- Investment & Partnership Insights : Gain actionable intelligence on Switzerland's biotech ecosystem, collaboration opportunities, and funding landscape to identify potential partnerships, acquisition targets, or investment opportunities in mRNA manufacturing.
- Regulatory & Operational Context : Understand Switzerland's regulatory framework, manufacturing standards, and operational requirements specific to mRNA production, enabling compliant market entry and efficient facility establishment in the country.
Frequently asked questions
What is the current size of Switzerland's mRNA synthesis and manufacturing market?
Switzerland's mRNA synthesis and manufacturing market was valued at USD 30.19 million in 2024.
What is the projected market size for Switzerland by 2029?
Switzerland's mRNA synthesis and manufacturing market is forecast to reach USD 36.54 million by 2029.
What is the CAGR for Switzerland's mRNA synthesis market?
Switzerland's mRNA synthesis and manufacturing market is expected to grow at a CAGR of 3.9% from 2024 to 2029.
Why is Switzerland important for mRNA manufacturing?
Switzerland is a global pharmaceutical and biotechnology hub with advanced research institutions, strong regulatory frameworks, and established life sciences infrastructure that support mRNA production and innovation.
What factors are driving growth in Switzerland's mRNA market?
Growth in Switzerland is driven by increasing demand for mRNA-based therapeutics and vaccines, expansion by CMOs and biopharmaceutical companies, and Switzerland's strategic position in the European mRNA supply chain.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the mRNA synthesis and manufacturing market. Exhaustive secondary research was done to collect information on the mRNA synthesis and manufacturing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as market share analysis, MnM repository analysis, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the mRNA synthesis and manufacturing market.
Secondary Research
The market for the companies offering mRNA synthesis and manufacturing solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product & service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. In the secondary research process, various secondary sources were referred to for identifying and collecting information related to the study. Secondary sources included annual reports, press releases, and investor presentations of blockchain vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and product-oriented perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global mRNA synthesis and manufacturing market scenario. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical & biopharmaceutical industry) and the supply side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, as well as channels) across five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, and online, personal, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Top-down approache was used to estimate and validate the total size of the mRNA synthesis and manufacturing market. These methods include market share analysis, MnM repository analysis were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the mRNA synthesis and manufacturing market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Market Definition
mRNA synthesis and manufacturing refers to the process of producing messenger RNA (mRNA) through in vitro transcription, followed by various purification, and characterization steps to create high-quality mRNA products suitable for research, therapeutic, or vaccine applications. The mRNA synthesis and manufacturing market encompasses the development, production, and commercialization of messenger RNA (mRNA) products, including their synthesis via in vitro transcription, large-scale manufacturing, and formulation. This market serves various applications such as vaccines, therapeutic treatments, and potentially other areas like protein replacement. It involves specialized technologies and equipment, adherence to regulatory standards, and a global supply chain network.
The study provides an in-depth analysis of the mRNA synthesis and manufacturing market based on contemporary market trends and developments, and its potential growth from 2024 to 2029. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key mRNA synthesis and manufacturing product and service providers.
Stakeholders
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Raw Material Suppliers
- Market Research and Consulting Firms
- Regulatory Agencies
- Venture Capitalists
- Government Organizations
- Industry Associations and Professional Societies
Report Objectives
- To define, describe, and forecast the mRNA synthesis and manufacturing market based on product, service, application, and region
- To define, describe, and forecast the mRNA synthesis and manufacturing market based on product by end user and service by end user
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the mRNA synthesis and manufacturing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global mRNA synthesis and manufacturing market and comprehensively analyze their products and services portfolios, market positions, and core competencies.
- To track and analyze competitive developments such as product/service launches, expansions, agreements, and collaborations in the mRNA synthesis and manufacturing market
- To benchmark players within the mRNA synthesis and manufacturing market using the Company Evaluation Matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Get the Full mRNA Synthesis & Manufacturing Market Report
Full forecast, segment splits, and company analysis for all mRNA Synthesis & Manufacturing Market.
- Canada mRNA Synthesis & Manufacturing Market
- US mRNA Synthesis & Manufacturing Market
- Germany mRNA Synthesis & Manufacturing Market
- UK mRNA Synthesis & Manufacturing Market
- France mRNA Synthesis & Manufacturing Market
- Italy mRNA Synthesis & Manufacturing Market
- Spain mRNA Synthesis & Manufacturing Market
- China mRNA Synthesis & Manufacturing Market
- Japan mRNA Synthesis & Manufacturing Market
- India mRNA Synthesis & Manufacturing Market
- South Korea mRNA Synthesis & Manufacturing Market
- Brazil mRNA Synthesis & Manufacturing Market
- Rest Of Europe mRNA Synthesis & Manufacturing Market
- Rest Of Asia Pacific mRNA Synthesis & Manufacturing Market
- Rest Of Latin America mRNA Synthesis & Manufacturing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
